Renovorx Inc (RNXT)

$0.95 -0.01 (-1.50%)
Market Cap 35.35M
Revenue (ttm) 40,000.00
Net Income (ttm) -8.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -22,025.00%
Debt to Equity Ratio 0.00
Volume 200,700
Avg Vol 263,194
Day's Range N/A - N/A
Shares Out 36.65M
Stochastic %K 39%
Beta 1.31
Analysts Strong Sell
Price Target $6.10

Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 284 4433
Fax: 650 397 4433
Address:
2570 West El Camino Real, Suite 320, Mountain View, United States
Rnxtsavior
Rnxtsavior Feb. 5 at 3:31 PM
$RNXT What a hire...lol. He's been involved in 3 takeover's. The best results from those if matched would get you a takeover at $1.49 a share. Congrats. There will be a reverse split.. maybe 1 for 20. That will get it to $20 per share then his premium gets it to $30 per share. They are not in it for the current shareholders to get rich.
1 · Reply
Wolfietrader
Wolfietrader Feb. 5 at 3:01 PM
$RNXT so today’s news of Mark Voll as new CFO: he saw three takeovers of tech companies. Techwell buys Intersil for cash at $18.50, a 49% premium. Montage bought by PDSTI for $21.50, a 25% premium, and Marvell acquiring Aquantia for $13.08, a 36% premium. All these companies were tech stocks, one which was Chinese. What is the expectation here? Takeover? I’m not thrilled with the premiums here. I hope this isn’t the plan right now.
0 · Reply
enzomassimi
enzomassimi Feb. 5 at 2:49 PM
$RNXT go now
0 · Reply
victory369
victory369 Feb. 5 at 2:25 PM
$RNXT I'm going to buy as much as I can today 😁💥🚀
0 · Reply
enzomassimi
enzomassimi Feb. 5 at 1:59 PM
$RNXT is better buy today !!!
0 · Reply
DARKP00L
DARKP00L Feb. 5 at 1:50 PM
$RNXT 08:39 on Feb. 05 2026 RenovoRx Appoints Mark Voll CFO, Effective Feb. 1 #tradeideas
0 · Reply
victory369
victory369 Feb. 5 at 1:21 PM
$RNXT Tomorrow is the day 💥🚀
0 · Reply
Mortz20
Mortz20 Feb. 4 at 11:53 PM
$RNXT On February 4, 2026, RenovoRx announced that new clinical data supporting the TAMP therapy platform will be presented at the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting, with the presentation scheduled for Friday, February 6, 2026 at 5:45–6:00 p.m. ET in the ePoster corridor. Highly suggest listening to this….could be a big Friday due to a hunch that Monday will be very green.
0 · Reply
Merlintrader
Merlintrader Feb. 4 at 8:58 PM
$RNXT https://www.merlintrader.com/rnxt-renovo-rx/
0 · Reply
victory369
victory369 Feb. 4 at 7:57 PM
$RNXT Let it go 💥🚀
0 · Reply
Latest News on RNXT
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

Feb 5, 2026, 8:30 AM EST - 19 hours ago

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

Feb 4, 2026, 8:30 AM EST - 1 day ago

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

Jan 28, 2026, 8:30 AM EST - 8 days ago

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

Jan 20, 2026, 8:30 AM EST - 16 days ago

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

Jan 14, 2026, 8:30 AM EST - 22 days ago

RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

Jan 8, 2026, 8:30 AM EST - 4 weeks ago

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

Dec 11, 2025, 8:30 AM EST - 2 months ago

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript

Dec 9, 2025, 2:57 PM EST - 2 months ago

RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

Dec 1, 2025, 8:30 AM EST - 2 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

Nov 19, 2025, 8:30 AM EST - 2 months ago

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

Nov 13, 2025, 4:05 PM EST - 3 months ago

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

Nov 6, 2025, 8:30 AM EST - 3 months ago

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

Nov 4, 2025, 8:30 AM EST - 3 months ago

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

Oct 27, 2025, 8:30 AM EDT - 3 months ago

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

Oct 9, 2025, 8:30 AM EDT - 4 months ago

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

Sep 25, 2025, 8:30 AM EDT - 4 months ago

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

Sep 11, 2025, 8:30 AM EDT - 5 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

Aug 20, 2025, 8:30 AM EDT - 6 months ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

Aug 14, 2025, 4:05 PM EDT - 6 months ago

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

Aug 6, 2025, 8:30 AM EDT - 6 months ago

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

Jul 28, 2025, 8:30 AM EDT - 6 months ago

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

Jul 14, 2025, 8:30 AM EDT - 7 months ago

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 9:07 PM EDT - 9 months ago

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025, 4:05 PM EDT - 9 months ago

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 14, 2025, 8:30 AM EDT - 9 months ago

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 6, 2025, 8:30 AM EDT - 9 months ago

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

May 1, 2025, 8:30 AM EDT - 10 months ago

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

Apr 29, 2025, 8:30 AM EDT - 10 months ago

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

Apr 16, 2025, 8:30 AM EDT - 10 months ago

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

Apr 4, 2025, 8:30 AM EDT - 10 months ago

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Apr 1, 2025, 8:30 AM EDT - 11 months ago

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

Mar 28, 2025, 8:00 AM EDT - 11 months ago

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

Mar 26, 2025, 8:00 AM EDT - 11 months ago

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

Mar 20, 2025, 8:00 AM EDT - 11 months ago

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

Mar 19, 2025, 8:00 AM EDT - 11 months ago

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

Feb 26, 2025, 8:00 AM EST - 1 year ago

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

Feb 13, 2025, 8:00 AM EST - 1 year ago

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 11, 2025, 7:00 AM EST - 1 year ago

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 8:49 PM EST - 1 year ago

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Proposed Public Offering

Feb 6, 2025, 4:05 PM EST - 1 year ago

RenovoRx Announces Proposed Public Offering

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

Feb 5, 2025, 2:14 AM EST - 1 year ago

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

Jan 27, 2025, 8:00 AM EST - 1 year ago

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

Jan 8, 2025, 8:00 AM EST - 1 year ago

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Dec 30, 2024, 8:00 AM EST - 1 year ago

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Nov 20, 2024, 8:45 AM EST - 1 year ago

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

Nov 14, 2024, 8:00 AM EST - 1 year ago

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Sep 25, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

Sep 19, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

Aug 27, 2024, 8:30 AM EDT - 1 year ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Aug 14, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Rnxtsavior
Rnxtsavior Feb. 5 at 3:31 PM
$RNXT What a hire...lol. He's been involved in 3 takeover's. The best results from those if matched would get you a takeover at $1.49 a share. Congrats. There will be a reverse split.. maybe 1 for 20. That will get it to $20 per share then his premium gets it to $30 per share. They are not in it for the current shareholders to get rich.
1 · Reply
Wolfietrader
Wolfietrader Feb. 5 at 3:01 PM
$RNXT so today’s news of Mark Voll as new CFO: he saw three takeovers of tech companies. Techwell buys Intersil for cash at $18.50, a 49% premium. Montage bought by PDSTI for $21.50, a 25% premium, and Marvell acquiring Aquantia for $13.08, a 36% premium. All these companies were tech stocks, one which was Chinese. What is the expectation here? Takeover? I’m not thrilled with the premiums here. I hope this isn’t the plan right now.
0 · Reply
enzomassimi
enzomassimi Feb. 5 at 2:49 PM
$RNXT go now
0 · Reply
victory369
victory369 Feb. 5 at 2:25 PM
$RNXT I'm going to buy as much as I can today 😁💥🚀
0 · Reply
enzomassimi
enzomassimi Feb. 5 at 1:59 PM
$RNXT is better buy today !!!
0 · Reply
DARKP00L
DARKP00L Feb. 5 at 1:50 PM
$RNXT 08:39 on Feb. 05 2026 RenovoRx Appoints Mark Voll CFO, Effective Feb. 1 #tradeideas
0 · Reply
victory369
victory369 Feb. 5 at 1:21 PM
$RNXT Tomorrow is the day 💥🚀
0 · Reply
Mortz20
Mortz20 Feb. 4 at 11:53 PM
$RNXT On February 4, 2026, RenovoRx announced that new clinical data supporting the TAMP therapy platform will be presented at the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting, with the presentation scheduled for Friday, February 6, 2026 at 5:45–6:00 p.m. ET in the ePoster corridor. Highly suggest listening to this….could be a big Friday due to a hunch that Monday will be very green.
0 · Reply
Merlintrader
Merlintrader Feb. 4 at 8:58 PM
$RNXT https://www.merlintrader.com/rnxt-renovo-rx/
0 · Reply
victory369
victory369 Feb. 4 at 7:57 PM
$RNXT Let it go 💥🚀
0 · Reply
Rnxtsavior
Rnxtsavior Feb. 4 at 7:28 PM
$RNXT Really looking strong going into Friday's presentation of clinical data. If it's selling off going in its going be ugly Friday!!
1 · Reply
TimmyTheSleuth
TimmyTheSleuth Feb. 4 at 4:54 PM
$RNXT remarkably solid during all this bullshit
1 · Reply
Wolfietrader
Wolfietrader Feb. 4 at 2:22 PM
$RNXT new clinical data being released on Friday. Good news always met with a falling price.
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 4 at 12:01 AM
$RNXT RSI: 45.94, MACD: 0.0099 Vol: 0.06, MA20: 1.02, MA50: 0.94 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
bowlerhatsftw
bowlerhatsftw Jan. 31 at 10:35 PM
$RNXT 1/31/26
2 · Reply
victory369
victory369 Jan. 30 at 8:57 PM
$RNXT
0 · Reply
victory369
victory369 Jan. 30 at 8:08 PM
$RNXT I’m in 🚀
1 · Reply
brandonscience
brandonscience Jan. 30 at 5:46 PM
$RNXT — Orin Hirschman (AIGH) disclosed ~7.1% ownership via 13G. Known for investing in capital hungry microcap biotechs with asymmetric upside. Not a pumper, but not a miracle worker either. Passive filing = no control play. Neutral-to-mildly bullish signal to me.
1 · Reply
Rnxtsavior
Rnxtsavior Jan. 30 at 2:48 PM
$RNXT So what's it going to be? Another little light volume up big volume down typical move? Which from under a buck start could take it to low .80's or worse... or do they let it back over a buck?
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Jan. 30 at 1:01 PM
$RNXT Today is last day to sign up to for FREE Warrants with every Share of Cancer fighting TPST . Acquisition in process. Do your own Due Diligence.
0 · Reply
Purple_Tip_Capital
Purple_Tip_Capital Jan. 29 at 2:54 PM
$RNXT this doesn’t seem good for us
1 · Reply
Rnxtsavior
Rnxtsavior Jan. 28 at 6:47 PM
$RNXT Wow... what a jump on the news. You know what happens every time??? Selling will start. This pig is exhausted. .80's then .70's. Then... we have to unfortunately reverse split. It's all coming.
0 · Reply